Sürdürülebilir Kalkınma Amaçları
Yazarlar
Yayınlar
- MakaleAçık Erişim2025Scopus SJRQ2EZH2 expression in colorectal carcinoma: an evaluation of clinicopathological and prognostic value
Cagatay, Diren Vuslat; Balci, Mecdi Gurhan; Issin, Gizem; Demir, Fatih
BackgroundEnhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2, catalyzes trimethylation of histone H3 lysine 27 and has been implicated in tumor progression.AimOur study aims to assess the relationship between EZH2 expression and clinicopathologic data, and survival in colorectal carcinomas (CRC).Materials and methodsEZH2 immunohistochemistry was performed on tumor blocks from 124 CRC patients. Based on H-scores, cases were stratified into low- and high-expression groups. EZH2 status was correlated with demographic, clinical, and pathologic features, and overall survival was analyzed with the Kaplan-Meier method and log-rank test.ResultsA total of 124 cases of CRC; 12 (9.7%) cases were classified as low EZH2 expression, and 112 (90.3%) cases were classified as high EZH2 expression. A significant association was found between EZH2 expression and microsatellite stability. High EZH2 expression was significantly enriched in microsatellite-stable tumors (p = 0.007) and in left-sided lesions (p = 0.049). No significant associations were detected with sex, stage, grade, lymph-node status, or vascular invasion. Kaplan-Meier analysis revealed no difference in overall survival between low- and high-EZH2 groups (log-rank p = 0.47; hazard ratio = 1.13, 95% CI 0.45-2.85). EZH2 staining was uniformly strong in normal mucosa and adenomas, mirroring the high expression observed in most CRCs.ConclusionsEZH2 is highly expressed across the normal-adenoma-carcinoma sequence and, in our cohort, was not linked to overall survival or to most clinicopathologic parameters in CRC. The lower expression observed in a subset of MSI-H tumors warrants further investigation; present evidence remains insufficient to establish EZH2 as an independent prognostic biomarker.
- MakaleAçık Erişim2020The Value of Cardiotrophin-1 in the Diagnosis, Severity, and Prognosis of Pulmonary Embolism
Pasli, Sinan; Asik, Olgun; Imamoglu, Melih; Çiçek, Mustafa; Yadigaroglu, Metin; Dogramaci, Seniz; Mentese, Ahmet; Sahin, Mursel; Tatli, Ozgur
Aim: Pulmonary embolism (PE) is a life-threatening condition that requires early diagnosis and treatment. There is still a need for precise and non-invasive biomarkers that can be used to diagnose PE. This study aimed to determine the diagnostic value of Cardiotrophin-1 (CT-1) in patients with acute PE and ascertain the relationship between serum CT-1 level and disease prognosis and severity. Materials and Methods: In this prospective study, the serum CT-1 levels of 165 patients with suspected acute PE were measured. The patients were divided into two groups, PE (+) and PE (-), based on their computed tomography angiography results. Their serum CT-1 levels were compared. Results: The CT-1 levels of the PE (+) group (median=4.18 pg/mL, range=3.57-9.55 pg/mL) was non-significantly (p=0.08) different from those of the PE (-) group (median=4.38 pg/mL, range=3.57-51.64 pg/mL). Based on the severity of the condition, there were significant differences (p=0.001) in the CT-1 levels of the patients in the intermediate-low risk group (median=4.19 pg/mL, range=3.62-5.32 pg/mL), intermediate-high risk group (median=4.06 pg/mL, range=3.57-9.31 pg/mL) and high risk group (median=5.01 pg/mL, range=3.89-9.55 pg/mL). Based on the clinical course, the CT-1 levels of the patients in the good clinical course group (median=4.15 pg/mL, range=3.57-9.31 pg/ml) were significantly different (p=0.004) from those in the poor clinical course group (median=4.53 pg/mL, range=3.66-9.55 pg/mL). Conclusion: CT-1 level was not observed to be a precise biomarker for the diagnosis of acute PE. However, our study demonstrated that the serum CT-1 levels can be used as a biomarker for ascertaining the severity and prognosis of patients with PE.
